Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells

Chemotherapy resistance represents a major obstacle for the treatment of patients with breast cancer (BC) and greatly restricts the therapeutic effect of the first-line chemotherapeutic agent doxorubicin (DOX). The present study aimed to investigate the feasibility of the recombinant dual-target mur...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yangwei, Ma, Ke, Jing, Jiayu, Wang, Chuying, Hu, Yuan, Shi, Yu, Li, Enxiao, Geng, Qianqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930415/
https://www.ncbi.nlm.nih.gov/pubmed/31892970
http://dx.doi.org/10.7150/jca.32765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930415/
https://www.ncbi.nlm.nih.gov/pubmed/31892970
http://dx.doi.org/10.7150/jca.32765

Ejemplares similares